sp 10

Peptide originally derived from SARS-CoV Spike (S) protein; corresponds to amino acid residues 668 to 679. Highly potent inhibitor of SARS-CoV S protein and ACE2 interaction (IC50 = 1.88 nM in biochemical assay). Inhibits interaction of SARS-CoV S protein and Vero E6 cells in vitro. Please note, this peptide displays 80% sequence identity to homologous site on SARS-CoV-2 S-protein (residues 689-697).

Surfactant protein A (SP-A) (196-215) is a synthetic peptide derived from the C-terminal carbohydrate recognition domain of human SP-A, specifically amino acids 196-215. This peptide suppresses LPS-induced TNF-α release in JAWSII mouse dendritic cells at 1 and 10 µM concentrations and promotes phagocytosis of P. aeruginosa at a 75 µM concentration. Furthermore, intratracheal administration of SP-A (196-215) at a dose of 50 µg per animal reduces disease severity and lung colony-forming units in mice infected with P. aeruginosa.

PACAP (1-38), human, ovine, rat TFA is an endogenous neuropeptide and a high-affinity agonist for the PAC1 receptor. This 38-amino acid peptide binds to the PAC1 receptor to activate adenylate cyclase, inducing an increase in intracellular cAMP levels and triggering downstream signaling. Research demonstrates that C-terminal amidation of PACAP (1-38), human, ovine, rat TFA is dispensable for its biological activity at the PAC1 receptor, with the non-amidated form retaining full agonistic potency. It plays crucial roles in neuroprotection, regulation of insulin secretion, and vasodilation.